Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
This review examines the role of model-informed drug development (MIDD) in advancing antibacterial and antiviral drug development, with an emphasis on the inclusion of host system dynamics into modeling efforts. Amidst the growing challenges of multidrug resistance and diminishing market returns, innovative methodologies are crucial for continuous drug discovery and development. The MIDD approach, with its robust capacity to integrate diverse data types, offers a promising solution. In particular, the utilization of appropriate modeling and simulation techniques for better characterization and early assessment of drug resistance are discussed. The evolution of MIDD practices across different infectious disease fields is also summarized, and compared to advancements achieved in oncology. Moving forward, the application of MIDD should expand into host system dynamics as these considerations are critical for the development of "live drugs" (e.g. chimeric antigen receptor T cells or bacteriophages) to address issues like antibiotic resistance or latent viral infections.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.addr.2024.115447 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
How Clinical Pharmacology Can Support Clinical Trial Diversity and Inclusion.
Clin Transl Sci
September 2025
Clinical Pharmacology Modeling and Simulation, GSK PLC, Durham, North Carolina, USA.
Enrolling diverse populations during early clinical trial development and planning for diversity plans could be challenging. In 2024, the Diversity and Inclusion Clinical Pharmacology Leadership Group Working Group (D&I CPLG WG) from The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) collaborated with the American Society for Clinical Pharmacology and Therapeutics (ASCPT) to develop a pre-conference session with speakers from industry, regulators, and IQ to utilize clinical pharmacology tools and implement the guidance on diversity plans toward improving the participation of under-represented populations in clinical trials. The pre-conference was well attended by industry, academia, as well as regulators and led to robust presentations and panel discussions through speaker sessions and case studies.
View Article and Find Full Text PDFApplication of Mechanistic Mathematical Modeling to Toxicology: Quantitative Systems Toxicology (QST).
Handb Exp Pharmacol
August 2025
GSK, Waltham, MA, USA.
Quantitative systems toxicology (QST) is emerging as an independent field of model-informed drug development (MIDD) with a focus on predicting toxicity endpoints. To enable toxicological predictions, QST models require incorporation of mechanistic details specific to safety applications including the ability to accurately model supratherapeutic doses and appropriately represent safety endpoints. Unique to the field of toxicology, mechanistic knowledge is often described through the use of adverse outcome pathways (AOPs), which formally represent existing knowledge about mechanisms of toxicity.
View Article and Find Full Text PDFModel-Informed Paradigm in Drug Development-An End-To-End Case Study From Upadacitinib Development.
Clin Transl Sci
August 2025
Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA.
Model-informed drug development (MIDD) entails applying quantitative approaches to assist with decision-making during drug development and has been used for dose optimization, to inform clinical trial design, and to support clinical trial waivers. With increasing cost and competitiveness in drug development, the use of tools that improve efficiency, like MIDD, is increasingly crucial. A unique case for the successful application of MIDD approaches from early Phase 1 through postapproval for the upadacitinib development program is described herein.
View Article and Find Full Text PDFEditorial: Application of PKPD modeling in drug discovery and development.
Front Pharmacol
June 2025
Department of Translation Medicine, Genfleet Therapeutics (Shanghai) Inc, China.
The dawn of a new era: can machine learning and large language models reshape QSP modeling?
J Pharmacokinet Pharmacodyn
June 2025
GSK, Collegeville, PA, USA.
Quantitative Systems Pharmacology (QSP) has emerged as a cornerstone of modern drug development, providing a robust framework to integrate data from preclinical and clinical studies, enhance decision-making, and optimize therapeutic strategies. By modeling biological systems and drug interactions, QSP enables predictions of outcomes, optimization of dosing regimens, and personalized medicine applications. Recent advancements in artificial intelligence (AI) and machine learning (ML) hold the potential to significantly transform QSP by enabling enhanced data extraction, fostering the development of hybrid mechanistic ML models, and supporting the introduction of surrogate models and digital twins.
View Article and Find Full Text PDF